Premier Alternatives

Santa Ana Bio

Alameda, CA · Founded 2020 · Privately Held (backing)

Operator of a biotechnology company intended to develop precision immunology for autoimmune diseases. Santa Ana Bio is based in Alameda, CA and was founded in 2020. Its last known valuation is $270 million. It has raised $203 million across 3 recorded rounds; the latest was a $20 million early-stage round in May 2024.

Last price · $/share
—
Implied valuation
$270.0M
Total raised
$203.0M
Last round
Early Stage VC
May 2024

Santa Ana Bio key facts

  • Operator of a biotechnology company intended to develop precision immunology for autoimmune diseases.
  • Santa Ana Bio’s last known valuation is $270.0M.
  • It has raised $203.0M across 3 recorded rounds; the latest was Early Stage VC ($20.0M) in May 2024.
  • Notable investors include Andreessen Horowitz, GV, RTW Investments, Versant Ventures, Access Biotechnology — 6 tracked in total.
  • Santa Ana Bio has filed 3 Form Ds with the SEC since 2021, most recently Jun 2024 ($20.0M sold to 10 investors).
  • Status: Privately Held (backing).
Free account
More of Santa Ana Bio with a free account
  • ·Watch Santa Ana Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Santa Ana Bio funding rounds

3 rounds
May 2024Early Stage VC$20.0MSEC filing▮
Feb 2023Early Stage VC$35.3MSEC filing▮
May 2021Early Stage VC$8.0MSEC filing▮
Full funding history →

Santa Ana Bio valuation

Santa Ana Bio's last known valuation is $270 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How much has Santa Ana Bio raised?

Santa Ana Bio has raised $203 million in total; 3 of its rounds are on record, from 2021 on. The largest on record was an $8 million early-stage round in May 2021; the most recent was a $20 million early-stage round in May 2024.

Santa Ana Bio has filed 3 Form Ds with the SEC since 2021, most recently in Jun 2024 ($20 million sold to 10 investors).

Santa Ana Bio investors

6 investors are on record for Santa Ana Bio, including Andreessen Horowitz, GV, RTW Investments and Versant Ventures. The early-stage round in May 2024 drew 10 investors.

About Santa Ana Bio

Operator of a biotechnology company intended to develop precision immunology for autoimmune diseases. The company leverages single-cell genomics and advanced analytics to design personalized biologics for autoimmune diseases, enabling patients to receive effective and targeted treatments that can lead to expected outcomes and improved quality of life.

Sector
Healthcare
HQ
Alameda, CA, United States
Founded
2020
Employees
38
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$270.0M

Santa Ana Bio’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.